Compare Abeona Therapeutics Inc (ABEO) vs 3M Company (MMM) Price & Performance

ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.

Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.

3M (MMM) trades at $182.89, up 1.21% today, with a bullish technical signal from moving averages and strong support at $180. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.40 exceeding the $2.25 estimate, and raised its full-year guidance. Revenue for 2025 was $24.95 billion, with a net income margin of 11.9% and a high return on equity of 82.77%. Recent news highlights strength in the Safety & Industrial segment and a partnership with Microsoft on EBO technology.

The outlook is positive due to operational improvements and innovation, but risks include litigation liabilities and macroeconomic pressures. Analysts are mixed with a consensus price target of $173.00, below the current price, suggesting cautious optimism. The stock's valuation metrics, such as a P/E of 32.49, indicate it may be fully priced, requiring careful monitoring of execution against raised guidance.